Boehringer Ingelheim Greece
This sponsor has funded 5 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 12887 | Finalised | A Multicentre, Cohort Study to Assess the Impact on SYMptom Burden and Patient Health-related Quality of Life of Afatinib Treatment in Advanced... | No | No |
| 17015 | Ongoing | Investigating idiopathic pulmonary fibrosis in Greece (INDULGE IPF) | No | No |
| 25664 | Ongoing | Investigating Trends in Quality of Life in Patients with Idiopathic Pulmonary Fibrosis (IPF) Under Treatment with Nintedanib (QUALIFY IPF) | No | No |
| 28719 | Ongoing | Changes in functional status in patients with COPD during therapy with Spiolto® Respimat® (Ellacto study) | Yes | No |
| 38426 | Ongoing | Quality of life and preference of COPD patients after Switching from Tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with Tiotropium... | No | No |
PAS by Risk Management Plan (RMP) requirement
Boehringer Ingelheim Greece
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Boehringer Ingelheim Greece
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Boehringer Ingelheim Greece
1 Study countries specified are the following:
- Greece